Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results